Tomorrow, Wednesday 12 November, the House of
Lords Public Services Committee will hear from two panels of
witnesses in evidence sessions focusing on issues surrounding the
manufacturing of medicines and pharmaceuticals in the UK. These
include exploring measures to make the medicine supply chain more
resistant to shortages and efforts to incentivise medicine
developers to develop and produce medicine in the UK.
The first session will start at 11:00am with the second
session following at 12.00pm. Both sessions can be watched live
or on demand at Parliament
TV or attend in person in Committee Room 1, Palace
of Westminster.
Giving evidence will be:
11:00am
-
Ian Wariner, Country Manager, Orion Pharma
(UK);
-
Darius Hughes, UK General Manager, Moderna;
and
-
, Besins Healthcare
UK Limited.
12:00pm
-
, Patient Access
Executive Director at Association of British Pharmaceuticals
Industry (ABPI);
-
Mark Samuels, Chief Executive, Medicines UK;
and
-
Dr , Director of
Policy and External Affairs at Bioindustry Association (BIA).
Questions will include:
- How would you respond to evidence that states “manufacturing
has been the most dominant root cause” of medicine supply issues
in the last five years?
- How are manufacturers incentivised to develop resilient
supply chains for their medicines and active pharmaceutical
ingredient (API) they use?
- How attractive is the UK as a location to manufacture
medicines? How could the Government better encourage manufactures
to develop and produce medicines in the UK?
- What recommendations should we make to the Government to
strengthen medicines security and develop stronger medicine
supply chains?
- How effectively is information on shortages and stock shared
across the supply chain, and how could this be improved?
